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inhibitor (EGFR TKI), geﬁtinib, was put on the market in 2002,
followed by erlotinib and afatinib. In the past 12 years, both
pros and cons of these drugs have emerged.1. Super responders to EGFR TKI and their
clinical backgrounds
In early-phase clinical trials, EGFR TKI showed dramatic
anti-tumor effects in certain patients with advanced lung
cancer refractory to standard cytotoxic agents. The success
was so impressive that health-care professionals as well as
patients and their families had great expectations of the drug.
Some early trials have indicated that geﬁtinib is more
effective in nonsmoking female patients with well-differen-
tiated adenocarcinoma.2. Efﬁcacy of EGFR TKI and EGFR gene status
Lynch et al. [1] reported groundbreaking results that revealed
that most lung cancer patients with EGFR gene mutation
responded to EGFR TKI, but those without the mutation did
not. The ﬁnding led to recognition of driver oncogenes and their
clinical implications.3. Ethnic differences and Asian studies
It was previously considered that nonsmoker patients
with lung cancer were relatively common in Asian countries,
and that the prognosis in these patients was relatively good.
However, the details were not clear, and this matter was not
investigated in Western countries. The discovery of EGFR
gene mutations and their relationship with the effect of EGFR
TKI focused attention on the fact that ethnic differences do
exist in terms of gene abnormalities. Thereafter, many
clinical trials aimed at proving the efﬁcacy of EGFR TKI were
conducted in Asian countries where this gene mutation is
common, and Asia has become the leader in mutation-based
clinical trials for lung cancer.4. Asian trials save Western patients
Studies of ethnic differences have been criticized because
of their racism-related implications, but this criticism missesY-NC-ND license.the point. Several clinical trials [2–4] conducted in Asian
countries showed that EGFR TKI is superior to standard
chemotherapy in patients with EGFR gene mutation, and
these results led to the approval of geﬁtinib in Western
countries, where gene-mutated patients represent the min-
ority of the population.5. Individualized medicine/BBM
Results from assorted basic and clinical research have
found applications in daily practice. The clinical practice
guideline for lung cancer by the Japan Lung Cancer Society
(JLCS) recommends determining EGFR gene status in adeno-
carcinoma before initiating drug therapy. The era of indivi-
dualized medicine or biomarker-based medicine for lung
cancer has arrived.6. OS or PFS?
It is known that EGFR TKI prolongs progression-free
survival (PFS) but not overall survival (OS) if patients receive
both chemotherapy and EGFR TKI. Current opinions differ as
to whether the primary endpoint of clinical trials to evaluate
the effect of drug therapy for lung cancer should be PFS or OS.7. Asian trial groups and publication
Since the development of EGFR TKI, the importance of
Asian studies has been globally recognized, and the achieve-
ments of Asian investigators have been gaining acclaim. In
Japan, many clinical trial groups such as JCOG, WJOG, and NEJ
are conducting clinical trials to accumulate evidence.8. Complicated resistance mechanism
However, the EGFR story is not all positive. It has been
shown that the effects of EGFR TKI have certain limitations,
i.e., effects depend on gene mutation status, de novo resis-
tance is seen in nearly 30% of patients with sensitive gene
mutations, and drug resistance is induced within one year in
patients initially sensitive to the drug. Recent studies [5–7]
have uncovered various resistance mechanisms such as
T790M mutation, C-Met gene ampliﬁcation, and hepatic
growth factor (HGF) overexpression. Elucidation of resistance
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drug resistance.9. ILD and drug safety
Another negative factor is drug-induced interstitial lung
disease (ILD). In Japan, three large-scale surveillance studies
[8–10] have shown that serious ILD occurs in 4–5% of patients
receiving EGFR TKI. In most patients, the ILD occurred within
two weeks after the start of administration, and 40–50% of
these patients died of rapidly progressive diffuse lung
damage. The risk factors for ILD are reported to be smoking,
squamous cell lung cancer, predisposing interstitial pneumo-
nia, and poor performance status. Regarding ILD, Japanese
patients appear to be more susceptible to ILD induced by
EGFR TKI than Western patients.10. Guidelines and COI
Considering the high incidence of severe ILD, the Japanese
Ministry of Health, Labour and Welfare requested the JLCS to
publish guidelines on proper use of geﬁtinib. Despite their
ﬁrm belief that the guidelines were prepared fairly and
appropriately, the JLCS faced criticism that some members
had serious conﬂicts of interest (COI), of which most mem-
bers had not been aware. This was a most unexpected and
unpleasant experience for the members concerned. Conse-
quently, the JLCS now strictly adheres to a COI policy,
including situations where decisions regarding guidelines
are involved.
Nevertheless, EGFR TKI has shifted our paradigm, and we
have learned much from the drug. It is important not to
neglect the negatives and to continue to develop standards
for optimized drug use.
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